Natixis Advisors LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 20.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 776,239 shares of the biopharmaceutical company’s stock after acquiring an additional 129,843 shares during the quarter. Natixis Advisors LLC’s holdings in Gilead Sciences were worth $95,276,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of the company. Heritage Trust Co boosted its position in Gilead Sciences by 9.0% during the 4th quarter. Heritage Trust Co now owns 42,945 shares of the biopharmaceutical company’s stock valued at $5,271,000 after acquiring an additional 3,545 shares in the last quarter. Camden National Bank bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $298,000. Allen Investment Management LLC bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $593,000. Crestmont Private Wealth LLC lifted its holdings in shares of Gilead Sciences by 5.1% during the fourth quarter. Crestmont Private Wealth LLC now owns 3,334 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 162 shares during the last quarter. Finally, Vantus Wealth LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $294,000. 83.67% of the stock is owned by institutional investors.
Insider Buying and Selling
In related news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares in the company, valued at $16,513,524.91. The trade was a 18.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the transaction, the chief financial officer owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock worth $9,047,570 in the last three months. Insiders own 0.30% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on GILD
Key Headlines Impacting Gilead Sciences
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead reported positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in primary biliary cholangitis, showing statistically significant ALP normalization versus placebo after 52 weeks. This adds to investor optimism around its liver disease franchise and broader growth prospects. Article Title
- Positive Sentiment: Separate coverage highlighted additional favorable Livdelzi data, including long-term efficacy and safety findings and a post hoc analysis showing sustained normalization of a key liver marker in PBC patients. These results reinforce confidence in the drug’s commercial potential. Article Title Article Title
- Positive Sentiment: Royal Bank of Canada upgraded Gilead from hold to moderate buy, which can bolster sentiment by signaling improved analyst confidence in the stock’s outlook.
- Positive Sentiment: Cencora announced it will support U.S. distribution of Kite’s FDA-approved CAR-T therapies, Yescarta and Tecartus, helping ensure continued commercialization and access for an important Gilead unit. Article Title
- Neutral Sentiment: Gilead also has several upcoming and recent oncology presentations with Kite at ASCO and EHA, which keep the company in focus but do not yet provide a clear near-term financial read-through. Article Title
- Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan. While routine, insider selling can still weigh on sentiment for some investors. Article Title
Gilead Sciences Price Performance
GILD stock opened at $127.57 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The firm has a market capitalization of $158.39 billion, a price-to-earnings ratio of 17.38 and a beta of 0.31. The firm has a 50 day moving average price of $135.10 and a 200-day moving average price of $134.26. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same period in the previous year, the business earned $1.81 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.
Gilead Sciences Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
